Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Autoantibodies and pain.
Dimethylfumarate Impairs Neutrophil Functions.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Neuroprotective effects of resident microglia following acute brain injury.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Interleukin-1beta promotes repair of the CNS.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Multiple sclerosis: pathogenesis and treatment.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Pages